Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 12/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21116575 | 0.82 | IDO1 (0.50) | FFAR1MAOBMRGPRX4 | |
| SCHEMBL3774293 | 0.82 | MRGPRX4 (0.68) | MAOBMRGPRX4NPC1HTTRAB9A | |
| SCHEMBL812098 | 0.80 | MAOB (0.44) | MAOBMAOA | |
| SCHEMBL27252705 | 0.79 | MAOB (0.74) | MAOBMRGPRX4MAOA | |
| SCHEMBL2438260 | 0.77 | MAOB (0.43) | FFAR1MAOBHTTSMN1; SMN2 | |
| SCHEMBL700133 | 0.77 | WDR5 (0.51) | MAOBLMNAHTTSMN1; SMN2 | |
| SCHEMBL10434846 | 0.76 | FFAR1 (0.52) | FFAR1MAOBTP53SMN1; SMN2 | |
| SCHEMBL13462917 | 0.76 | MAOB (0.60) | MAOBHTTSMN1; SMN2MAOA | |
| SCHEMBL4701201 | 0.76 | MRGPRX4 (0.65) | MAOBMRGPRX4NPC1LMNAHTT | |
| SCHEMBL14547318 | 0.75 | MAOB (0.81) | MAOBMRGPRX4NPC1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1926737-B1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-03-15 | — | — | EP | disclosed |
| EP-1926737-A1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007031428-A1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060607-A1 | 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives | BARTKOVITZ DAVID J | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060607-A1 | 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives | BRAF, RAF1, MAP3K7 | FFAR1 2605/4885MAOB 1364/4885MRGPRX4 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.